$19.39 -$0.51 (-2.5%)

04:00 PM EST on 11/13/19

Alkermes, Inc. (NASDAQ:ALKS)

CAPS Rating: 4 out of 5

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.

Current Price $19.39 Mkt Cap $3.1B
Open $19.72 P/E Ratio 0.00
Prev. Close $19.90 Div. (Yield) $0.00 (0.0%)
Daily Range $19.33 - $19.96 Volume 2,353,877
52-Wk Range $17.11 - $37.75 Avg. Daily Vol. 1,407,724

Caps

How do you think NASDAQ:ALKS will perform against the market?

Add Stock to CAPS Watchlist

All Players

321 Outperform
13 Underperform
 

All-Star Players

62 Outperform
2 Underperform
 

Wall Street

10 Outperform
0 Underperform
 

Top NASDAQ:ALKS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

airenInDebt (64.87)
Submitted August 09, 2018

Several meds currrently in the 3rd stage of the pipeline, two on the market with one being a treatment for opiod addiction makes this a solid investment. A bonus is investing in a company whose products can actually save lives.

PickThatBooger (29.06)
Submitted November 15, 2010

Almost got the top on this one.

Recent Community Commentary

Read the most recent pitches from players about ALKS.

Recs

1
Member Avatar airenInDebt (64.87) Submitted: 8/9/2018 4:18:27 PM : Outperform Start Price: $44.59 NASDAQ:ALKS Score: -65.57

Several meds currrently in the 3rd stage of the pipeline, two on the market with one being a treatment for opiod addiction makes this a solid investment. A bonus is investing in a company whose products can actually save lives.

Recs

0
Member Avatar XMFRendezvous (93.83) Submitted: 4/21/2018 1:17:56 AM : Outperform Start Price: $46.31 NASDAQ:ALKS Score: -73.79

Alkermers is primarily involved in producing generic versions or "biosimilars" of already marketed name-brand drugs. The Affordable Care Act encourages the use of generic drugs, which are cheaper. R&D costs are lower, but so are the margins. This is a socially responsible business model, and is the the direction the pharmaceutical industry is headed.

Recs

0
Member Avatar InvestRight (78.85) Submitted: 4/2/2018 4:42:44 PM : Outperform Start Price: $45.02 NASDAQ:ALKS Score: -76.34

Drop is just a better oppurtunity to buy. Management strongly disagrees with the decision and even if they are wrong this biotech is innovating.

Leaderboard

Find the members with the highest scoring picks in ALKS.

Score Leader

Gib323

Gib323 (< 20) Score: +622.96

The Score Leader is the player with the highest score across all their picks in ALKS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
optigon123 < 20 7/20/2009 Underperform 3M $10.57 +83.44% +228.04% +144.60 0 Comment
scottidog 48.55 9/29/2010 Underperform 5Y $14.61 +32.72% +170.45% +137.73 0 Comment
boardsecurities 29.21 8/2/2013 Underperform 5Y $33.73 -42.51% +81.54% +124.05 0 Comment
cmc1981 30.14 3/31/2014 Underperform 5Y $43.77 -55.70% +65.27% +120.97 0 Comment
AnotherOldFart 24.76 10/12/2006 Underperform 3M $15.58 +24.45% +142.07% +117.62 0 Comment
dwn88ir 64.78 4/23/2012 Underperform 5Y $17.47 +10.99% +126.40% +115.40 0 Comment
cthomas1017 99.10 8/8/2012 Underperform 5Y $17.73 +9.36% +120.64% +111.28 0 Comment
hoochkitty 33.36 8/24/2007 Underperform 5Y $16.79 +15.49% +120.70% +105.21 0 Comment
alvinbentley 29.24 6/30/2008 Underperform 5Y $12.55 +54.50% +148.13% +93.62 0 Comment
DoctorStox 92.29 6/13/2007 Underperform 1Y $14.47 +34.00% +117.15% +83.15 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ALKS.